These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1689737

  • 1. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration.
    Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V.
    J Clin Endocrinol Metab; 1990 Mar; 70(3):675-9. PubMed ID: 1689737
    [Abstract] [Full Text] [Related]

  • 2. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP, Ratanachaiyavong S, Middleton GW, Love W, John R, Owen GM, Darke C, Lazarus JH, Hall R, McGregor AM.
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [Abstract] [Full Text] [Related]

  • 3. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET, Steel NR, Taylor JJ, Stephenson AM, Stratton A, Holcombe M, Kendall-Taylor P.
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [Abstract] [Full Text] [Related]

  • 4. A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype.
    Allannic H, Fauchet R, Lorcy Y, Gueguen M, Le Guerrier AM, Genetet B.
    J Clin Endocrinol Metab; 1983 Oct; 57(4):719-22. PubMed ID: 6688428
    [Abstract] [Full Text] [Related]

  • 5. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
    Madec AM, Allannic H, Genetet N, Gueguen M, Genetet G, Fauchet R, Stefanutti A, Orgiazzi J.
    J Clin Endocrinol Metab; 1986 Jan; 62(1):117-21. PubMed ID: 3484386
    [Abstract] [Full Text] [Related]

  • 6. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A.
    N Engl J Med; 1996 Jan 25; 334(4):220-4. PubMed ID: 8531998
    [Abstract] [Full Text] [Related]

  • 7. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
    García-Mayor RV, Páramo C, Luna Cano R, Pérez Mendez LF, Galofré JC, Andrade A.
    J Endocrinol Invest; 1992 Dec 25; 15(11):815-20. PubMed ID: 1283984
    [Abstract] [Full Text] [Related]

  • 8. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G, Massart C, Hody B, Poirier JY, Lé Reun M, Hespel JP, Leclech G, Simon M.
    BMJ; 1989 Feb 11; 298(6670):359-61. PubMed ID: 2564286
    [Abstract] [Full Text] [Related]

  • 9. Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment.
    Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H.
    Clin Endocrinol (Oxf); 1999 Jan 11; 50(1):127-32. PubMed ID: 10341866
    [Abstract] [Full Text] [Related]

  • 10. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C, Duan Y, Wu X.
    Zhonghua Yi Xue Za Zhi; 2000 Nov 11; 80(11):835-7. PubMed ID: 11218878
    [Abstract] [Full Text] [Related]

  • 11. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study.
    Teng CS, Yeung RT.
    J Clin Endocrinol Metab; 1980 Jan 11; 50(1):144-7. PubMed ID: 6892512
    [Abstract] [Full Text] [Related]

  • 12. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, Farah CS, Reis LC.
    J Clin Endocrinol Metab; 1983 Sep 11; 57(3):563-70. PubMed ID: 6192139
    [Abstract] [Full Text] [Related]

  • 13. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1998 Mar 11; 83(3):814-8. PubMed ID: 9506733
    [Abstract] [Full Text] [Related]

  • 14. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study.
    Léger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, French Childhood Graves' Disease Study Group.
    J Clin Endocrinol Metab; 2012 Jan 11; 97(1):110-9. PubMed ID: 22031519
    [Abstract] [Full Text] [Related]

  • 15. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE.
    J Clin Endocrinol Metab; 1993 Apr 11; 76(4):928-32. PubMed ID: 7682562
    [Abstract] [Full Text] [Related]

  • 16. [Relapse in Basedow's disease after treatment with synthetic antithyroid drugs. Prognostic value of analysis of the HLA system].
    Allannic H, Fauchet R, Lorcy Y, Gueguen M, Le Guerrier AM, Genetet B.
    Presse Med; 1983 Dec 03; 12(44):2797-800. PubMed ID: 6228849
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
    Grebe SK, Feek CM, Ford HC, Fagerström JN, Cordwell DP, Delahunt JW, Toomath RJ.
    Clin Endocrinol (Oxf); 1998 May 03; 48(5):585-92. PubMed ID: 9666870
    [Abstract] [Full Text] [Related]

  • 18. Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse.
    Gong ST, Chao IM.
    J Formos Med Assoc; 1991 Dec 03; 90(12):1155-62. PubMed ID: 1724781
    [Abstract] [Full Text] [Related]

  • 19. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan 03; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 20. Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission.
    Dahlberg PA, Karlsson FA, Jansson R, Wide L.
    J Clin Endocrinol Metab; 1985 Dec 03; 61(6):1100-4. PubMed ID: 2414311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.